Ankara Training and Research Hospital, Ophthalmology Department, University of Health Sciences, Ankara, Turkey.
Ankara City Hospital, Ophthalmology Department, University of Health Sciences, Ankara, Turkey.
Cutan Ocul Toxicol. 2020 Sep;39(3):237-243. doi: 10.1080/15569527.2020.1778016. Epub 2020 Jun 26.
To examine central macular, RNFL (retinal nerve fibre layer), GCC (ganglion cell complex) thicknesses; and VEPs (visual evoked potential) in epileptic patients using levetiracetam for at least one year.
Sixteen focal epileptic patients receiving levetiracetam monotherapy and 16 healthy subjects were included in the study. Central macular, RNFL and GCC thicknesses according to spectral domain OCT (optical coherence tomography); and VEPs parameters were compared between patients and healthy subjects.
The mean age of patient and control groups were 40 ± 16 and 38 ± 12 years respectively ( > 0.05). The patient group was on levetiracetam therapy for 64 ± 45 (12-168) months. Central macular thickness was thinner in the patient group ( = 0.008). There was no difference among groups regarding RNFL thicknesses. GCC thicknesses in all quadrants were similar among groups, except the superior quadrant; which was thinner in the patient group ( = 0.03). P100 amplitude in 30 min pattern was lower in the patient group ( = 0.04). N135 latency in 15 min ( = 0.03) and 7 min patterns ( = 0.01) was longer in the patient group.
Central macular and GCC thicknesses; and VEP parameters in patients receiving levetiracetam treatment may differ from healthy subjects.
用左乙拉西坦治疗至少一年，检查癫痫患者的中央黄斑、RNFL（视网膜神经纤维层）、GCC（节细胞复合体）厚度和 VEP（视觉诱发电位）。
将 16 例接受左乙拉西坦单药治疗的局灶性癫痫患者和 16 例健康受试者纳入研究。比较患者和健康受试者之间根据光谱域 OCT（光学相干断层扫描）的中央黄斑、RNFL 和 GCC 厚度和 VEP 参数。
患者组和对照组的平均年龄分别为 40±16 岁和 38±12 岁（>0.05）。患者组接受左乙拉西坦治疗的时间为 64±45 个月（12-168 个月）。中央黄斑厚度在患者组中较薄（=0.008）。各组间 RNFL 厚度无差异。除了上象限，各组间 GCC 厚度相似，而上象限在患者组中较薄（=0.03）。30 分钟模式的 P100 振幅在患者组中较低（=0.04）。15 分钟（=0.03）和 7 分钟模式（=0.01）的 N135 潜伏期在患者组中较长。
接受左乙拉西坦治疗的患者的中央黄斑和 GCC 厚度以及 VEP 参数可能与健康受试者不同。
